Grassley, however, likened the FDA's handling of Vioxx to the controversy over the FDA's treatment of the use of anti-depressants in children. In that case, another FDA scientist who raised an alarm about the anti-depressants was prohibited from presenting his findings at an FDA advisory committee meeting.
Graham did present his findings at the conference in France, and just last week he delivered his final report to the FDA. In that final report he estimated that, given the 20 million Americans who had taken Vioxx, it was likely that there had been more than 27,000 cases of heart attacks and sudden cardiac deaths associated with the drug.
But despite the strong warnings from their own scientist, it was not the FDA, but Merck, the maker of Vioxx, who ultimately removed the drug from the market.